Cargando…

Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population‐based cohort study

OBJECTIVE: This population‐based study examined the association between baseline uric acid (UA) and prostate cancer (PCa)‐related mortality amongst PCa patients receiving androgen deprivation therapy (ADT). METHODS: Adults with PCa who received ADT in Hong Kong between December 1999 and March 2021 w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yan Hiu Athena, Chan, Jeffrey Shi Kai, Leung, Chi Ho, Hui, Jeremy Man Ho, Dee, Edward Christopher, Ng, Kenrick, Liu, Kang, Liu, Tong, Tse, Gary, Ng, Chi Fai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	BRIEF COMMUNICATION
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501275/ https://www.ncbi.nlm.nih.gov/pubmed/37455552 http://dx.doi.org/10.1002/cam4.6344

Ejemplares similares

Metformin use and hospital attendance‐related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based cohort study
por: Lee, Yan Hiu Athena, et al.
Publicado: (2023)

HbA1c Variability and Cardiovascular Events in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2022)

Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based study
por: Lee, Yan Hiu Athena, et al.
Publicado: (2022)

Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2023)

Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study
por: Ng, Chi-fai, et al.
Publicado: (2020)

Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis
por: Chan, Jeffrey S. K., et al.
Publicado: (2022)

Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective
por: Collier, Tony, et al.
Publicado: (2020)

Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma
por: Lee, Chi-Ho, et al.
Publicado: (2017)

Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
por: Teoh, Jeremy YC, et al.
Publicado: (2017)

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
por: Shaw, Greg L., et al.
Publicado: (2016)

Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population‐based cohort study
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2023)

Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy
por: Yu, Simon Chun Ho, et al.
Publicado: (2016)

Hsa-miRNA-765 as a Key Mediator for Inhibiting Growth, Migration and Invasion in Fulvestrant-Treated Prostate Cancer
por: Leung, Yuet-Kin, et al.
Publicado: (2014)

Correction: Hsa-miRNA-765 as a Key Mediator for Inhibiting Growth, Migration and Invasion in Fulvestrant-Treated Prostate Cancer
por: Leung, Yuet-Kin, et al.
Publicado: (2019)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Association between immune checkpoint inhibitors and myocardial infarction in Asians: A population‐based self‐controlled case series
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2023)

Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy
por: Johnson, Lisa DS, et al.
Publicado: (2014)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
por: Xu, Ziyang, et al.
Publicado: (2022)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021)

Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
por: Jia, Lin, et al.
Publicado: (2018)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer
por: Choi, Se Young, et al.
Publicado: (2021)

Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination
por: Lee, Sung Uk, et al.
Publicado: (2017)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
por: Leung, David Ka-Wai, et al.
Publicado: (2021)

Time trend and characteristics of prostate cancer diagnosed in Hong Kong (China) in the past two decades
por: Wong, Ho-Fai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ivnal53f2c3oaoeppgk9r6si26